SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals surges on reporting 23% growth in Q2 consolidated net profit

21 Oct 2014 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 407.90, up by 9.00 points or 2.26% from its previous closing of Rs. 398.90 on the BSE.

The scrip opened at Rs. 404.10 and has touched a high and low of Rs. 411.00 and Rs. 400.00 respectively. So far 14249 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 449.70 on 16-Sep-2014 and a 52 week low of Rs. 168.00 on 21-Oct-2013.

Last one week high and low of the scrip stood at Rs. 414.40 and Rs. 381.00 respectively. The current market cap of the company is Rs. 7651.86 crore.

The promoters holding in the company stood at 74.13% while Institutions and Non-Institutions held 11.12% and 14.76% respectively.

Alembic Pharmaceuticals has registered 31.67% rise in its net profit at Rs 84.05 crore for the quarter under review as compared to Rs 63.83 crore for the same quarter in the previous year. However, total income of the company has increased 11.54% at Rs 541.52 crore for Q2FY15 as compared Rs 485.46 crore for the corresponding quarter previous year.

On consolidated basis, the company’s net profit after taxes and minority interest for the quarter under review registered 23.35% growth at Rs 77.27 crore against Rs 61.64 crore in the September quarter of previous fiscal. The company’s total income has increased by 12.46% at Rs 547.22 crore for the quarter under review from Rs 486.56 crore in the similar quarter of previous year.

Alembic Pharma Share Price

772.85 -12.10 (-1.54%)
20-Apr-2026 12:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.80
Dr. Reddys Lab 1238.00
Cipla 1238.25
Zydus Lifesciences 942.95
Lupin 2333.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×